Combinations of drugs in the Treatment of Obesity
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Obesity is a chronic disease associated with excess morbidity and mortality. Clinical treatment, however, currently offers disappointing results, with very high rates of weight loss failure or weight regain cycles, and only two drugs (orlistat and sibutramine) approved for long-term use. Drugs combinations can be an option for its treatment but, although widely used in clinical practice, very few data are available in literature for its validation. Our review focuses on the rationale for their use, with advantages and disadvantages; on combinations often used, with or without studies; and on new perspectives of combinations being studied mainly by the pharmaceutical industry.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
Valvular heart disease associated with fenfluramine-phentermine
Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632
Inhibition of Food Intake in Obese Subjects by Peptide YY 3–36
Batterham, R. L., Cohen, M. A., Ellis, S. M., Le Roux, C. W., Withers, D. J., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030204 · Cited by 1,604 · cited 1×
“Peptide YY (PYY 3-36) is gut hormone which is also secreted after a meal [37,59].”
BackgroundDeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 1×
“Peripheral administration of GLP-1 in obese diabetic subjects demonstrated a reduction in food ingestion [56].”
BackgroundCause-Specific Excess Deaths Associated With Underweight, Overweight, and Obesity
Flegal, K. M., Graubard, B. I., Williamson, D. F., & Gail, M. H. (2007) · JAMA · doi:10.1001/jama.298.17.2028 · Cited by 1,542 · cited 1×
“This is associated with a significant increase of comorbidities such as type 2 diabetes mellitus (T2DM), hypertension, cardiovascular disease, obstructive sleep apnea, musculoskeletal diseases and neoplasias [2].”
BackgroundHeymsfield, S. B., Greenberg, A. S., Fujioka, K., Dixon, R. M., Kushner, R., Hunt, T., Lubina, J. A., Patane, J., Self, B., Hunt, P., et al. (1999) · JAMA · doi:10.1001/jama.282.16.1568 · Cited by 1,422
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 2×
“Glucagon-like peptide 1 (GLP-1) is a gut hormone rapidly secreted in response to food intake [55].”
BackgroundGastrointestinal regulation of food intake
Cummings, D. E., & Overduin, J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30227 · Cited by 1,216 · cited 4×
“The control of energy homeostasis and body weight involves complex interactions between the CNS and peripheral neurohormonal signals from the adipose tissue, pancreas and GI tract [36,37,47].”
BackgroundInfluentialAstrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Long term pharmacotherapy for obesity and overweight: updated meta-analysis
Rucker, D., Padwal, R., Li, S. K., Curioni, C., & Lau, D. C. W. (2007) · BMJ · doi:10.1136/bmj.39385.413113.25 · Cited by 801
Douketis, J. D., Macie, C., Thabane, L., & Williamson, D. F. (2005) · International Journal of Obesity · doi:10.1038/sj.ijo.0802982 · Cited by 665 · cited 3×
“This is associated with a significant increase of comorbidities such as type 2 diabetes mellitus (T2DM), hypertension, cardiovascular disease, obstructive sleep apnea, musculoskeletal diseases and neoplasias [2].”
BackgroundRosenbaum, M. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25977 · Cited by 575 · cited 1×
“However, in obese patients without leptin deficiency, the administration of this substance alone in monotherapy, even in high pharmacological doses, failed to produce substantial weight loss [51].”
BackgroundShekelle, P. G., Hardy, M. L., Morton, S. C., Maglione, M., Mojica, W. A., Suttorp, M. J., Rhodes, S. L., Jungvig, L., & Gagné, J. (2003) · JAMA · doi:10.1001/jama.289.12.1537 · Cited by 511
Bupropion SR Enhances Weight Loss: A 48‐Week Double‐Blind, Placebo‐ Controlled Trial
Anderson, J. W., Greenway, F. L., Fujioka, K., Gadde, K. M., McKenney, J., & O'Neil, P. M. (2002) · Obesity Research · doi:10.1038/oby.2002.86 · Cited by 315 · cited 3×
“The treatment of these illnesses with antidepressants many times results in weight variation, depending on the drug class that is used [15,34,64,65].”
BackgroundComparison of continuous and intermittent anorectic therapy in obesity.
Munro, J. F., MacCuish, A. C., Wilson, E. M., & Duncan, L. J. (1968) · BMJ · doi:10.1136/bmj.1.5588.352 · Cited by 215 · cited 1×
“Weight loss is the result of the reduction of caloric ingestion through reduced appetite, with previous randomized studies showing reductions of 5 to 15% of initial weight in up to 60% of the patients after 16 to 36 weeks of treatment [13,14].”
MethodComparison of Combined Bupropion and Naltrexone Therapy for Obesity with Monotherapy and Placebo
Greenway, F. L., Dunayevich, E., Tollefson, G., Erickson, J., Guttadauria, M., Fujioka, K., Cowley, M. A., & for the NB-201 Study Group (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1350 · Cited by 179 · cited 1×
“A double-blind phase 2 randomized study with a 24-week duration, with 419 patients, compared three different doses of immediate release (IR) naltrexone (16, 32 and 48 mg/d), in combination with bupropion sustained release (SR), 400 mg/d, with placebo, bupropion SR, 400 mg/d, and naltrexone IR, 48 mg/d, in monotherapy…”
MethodSmith, S. R., Aronne, L. J., Burns, C. M., Kesty, N. C., Halseth, A. E., & Weyer, C. (2008) · Diabetes Care · doi:10.2337/dc08-0029 · Cited by 172 · cited 2×
“In previous studies with obese patients on monotherapy, this hormone showed maintained and prolonged weight loss [49].”
BackgroundCercato, C., Roizenblatt, V. A., Leança, C. C., Segal, A., Lopes Filho, A. P., Mancini, M. C., & Halpern, A. (2009) · International Journal of Obesity · doi:10.1038/ijo.2009.124 · Cited by 100
Self-citationHow Physician Obesity Specialists Use Drugs to Treat Obesity
Hendricks, E. J., Rothman, R. B., & Greenway, F. L. (2009) · Obesity · doi:10.1038/oby.2009.69 · Cited by 97 · cited 4×
“After this publication, one retrospective review of 22 patients sent by one of the members of the American Society of Bariatric Physicians showed that after six months of treatment with phentermine (with a weight loss of 16%), the addition of 5-HTP-Carbidopa resulted in an extra weight loss of 1% in the next six month…”
BackgroundInfluentialPharmacotherapy of Eating Disorders
Jackson, C. W., Cates, M., & Lorenz, R. (2010) · Nutrition in Clinical Practice · doi:10.1177/0884533610362239 · Cited by 28
Cited by
Food sustainability: problems, perspectives and solutions
Garnett, T. (2013) · Proceedings of the Nutrition Society · doi:10.1017/s0029665112002947 · Cited by 380
AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity
Grunvald, E., Shah, R., Hernaez, R., Chandar, A. K., Pickett-Blakely, O., Teigen, L. M., Harindhanavudhi, T., Sultan, S., Singh, S., & Davitkov, P. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.08.045 · Cited by 347
Emerging pharmacotherapies for obesity: A systematic review
Kokkorakis, M., Chakhtoura, M., Rhayem, C., Al Rifai, J., Ghezzawi, M., Valenzuela-Vallejo, L., & Mantzoros, C. S. (2025) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001045 · Cited by 102
Lundkvist, P., Pereira, M. J., Katsogiannos, P., Sjöström, C. D., Johnsson, E., & Eriksson, J. W. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12954 · Cited by 72
Metadata
- Authors
- Halpern, B., Oliveira, E. S. L., Faria, A. M., Halpern, A., Melo, M. E. D., Cercato, C., & Mancini, M. C.
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2010-07-27
- Volume
- 3
- Issue
- 8
- Pages
- 2398-2415
- ISSN
- 1424-8247 (ISSN-L)
- OpenAlex
- W2006178653
- Cited by
- 35
- References
- 21
- FWCI
- 1.23
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.